Ohne eingeschaltetes JavaScript können Sie PSIAC nicht in vollem Umfang nutzen.
Literaturverzeichnis
Zhao XJ. Xenobiotica. Oct 2002; 32(10): 863-78
Pubmed [439]
Zhao Y. Br J Clin Pharmacol. Dec 2021; 87(12): 4823-4830
Pubmed [12587]
Zheng C. Drug Des Devel Ther. Oct 2017; 11: 2957-2968
Pubmed [11525]
Zheng W. J Clin Psychopharmacol. Jun 2017; 37(3): 341-346
Pubmed [11602]
Zheng Y. Cancer Biol Ther. Mar 2017; 18(3): 132-136
Pubmed [10944]
Zhi J. J Clin Pharmacol. Sep 2002; 42(9): 1011-9
Pubmed [3209]
Zhou D. Drug Metab Dispos. Apr 2011; 39(4): 703-10
Pubmed [9353]
Zhou D. Drug Metab Dispos. May 2010; 38(5): 863-70
Pubmed [4986]
Zhou D. J Antimicrob Chemother. Mar 2020
Pubmed [8577]
Zhou HH. Clin Pharmacol Ther. Jun 1990; 47(6): 686-93
Pubmed [4184]
Zhou R. Med Sci Monit. Dec 2021; 27: e934043
Pubmed [12118]
Zhou S. Clin Pharmacokinet. Jan 2005; 44(3): 279-304
Pubmed [5847]
Zhou SF. Clin Pharmacokinet. Jan 2009; 48(12): 761-804
Pubmed [125]
Zhou SF. Curr Drug Metab. Jun 2008; 9(5): 394-409
Pubmed [2850]
Zhou SF. Curr Drug Metab. May 2008; 9(4): 310-22
Pubmed [6402]
Zhou SF. Curr Med Chem. Jan 2009; 16(27): 3480-675
Pubmed [2113]
Zhou SF. Ther Drug Monit. Dec 2007; 29(6): 687-710
Pubmed [2650]
Zhou W. Clin Pharmacol Ther. Jul 2018; 104(1): 188-200
Pubmed [7714]
Zhou XJ. Antimicrob Agents Chemother. Jul 2006; 50(7): 2309-15
Pubmed , Volltext , DOI [7083]
Zhou-Pan XR. Cancer Res. Nov 1993; 53(21): 5121-6
Pubmed [4835]
Zhu J. Free Radic Biol Med. Apr 2019; 134: 9-22
Pubmed [10687]
Zhu L. Antivir Ther. Jan 2010; 15(8): 1107-14
Pubmed [9375]
Zhu M. Antimicrob Agents Chemother. Jun 2009; 53(6): 2346-53
Pubmed , Volltext , DOI [3039]
Zhu M. Drug Metab Dispos. Apr 2005; 33(4): 500-7
Pubmed [12596]
Zhu XM. Schizophr Res. Jul 2018; 197: 288-293
Pubmed [13438]
Zhu XQ. J Clin Pharm Ther. Feb 2018; 43(1): 141-144
Pubmed [7312]
Zhu Y. Drug Metab Dispos. Feb 2014; 42(2): 245-9
Pubmed [10192]
Ziegler D. Diabetes Metab Res Rev. May 2008; 24 Suppl 1: S52-7
Pubmed [11555]
Ziegler M. Mov Disord. Apr 2003; 18(4): 418-25
Pubmed [10436]
Zientek M. J Pharmacol Toxicol Methods. Nov 2008; 58(3): 206-14
Pubmed [10569]
Ziffra M. Ann Clin Psychiatry. May 2021; 33(2): 124-133
Pubmed [12124]
Zilly W. Clin Pharmacokinet. Jan 1977; 2(1): 61-70
Pubmed [6261]
Zilly W. Verh Dtsch Ges Inn Med. Jan 1974; 80: 1538-40
Pubmed [5767]
Zimbron J. Eur Neuropsychopharmacol. Sep 2016; 26(9): 1353-1365
Pubmed [7992]
Zimmer R. Acta Psychiatr Scand Suppl. Jan 1990; 360: 84-6
Pubmed [1926]
Zimmerman HJ. Hepatology. Sep 1995; 22(3): 767-73
Pubmed [3503]
Zimmerman JJ. Pharmacotherapy. Jul 2008; 28(7): 895-905
Pubmed [7318]
Zimmerman T. Clin Neuropharmacol. Apr 1991; 14(2): 165-9
Pubmed [10968]
Zimmermann AE. Clin Infect Dis. Jan 2006; 42(2): 283-90
Pubmed [5687]
Zini R. Int J Clin Pharmacol Ther Toxicol. Feb 1991; 29(2): 64-6
Pubmed [10049]
Zink M. Pharmacopsychiatry. May 2006; 39(3): 109-11
Pubmed [10487]
Zirkle GA, King PD, McAtee OB, Van Dyke R. Effects of chlorpromazine and alcohol on coordination and judgment. JAMA (1959) 171, 1496-9 [817]
Zirwas MJ. Dermatitis. Dec 2006; 17(4): 208-10
Pubmed [8917]
Zisook S. Biol Psychiatry. Feb 2006; 59(3): 203-10
Pubmed [8405]
Zitelli BJ. Clin Pediatr (Phila). Mar 1987; 26(3): 117-9
Pubmed [5863]
Zitron E. Circulation. Feb 2005; 111(7): 835-8
Pubmed [11682]
Zoccali et al. (2007) J Clin Psychopharmacol 93:109-116 [1144]
Zoccali R. Pharmacol Res. Oct 2003; 48(4): 411-4
Pubmed [2545]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics, Novembet 2001 [2504]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics. November 2001 [2078]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., November 2001 [1646]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., Novembet 2001 [945]
Zoleptil (Zotepine). Knoll Limited. Summary of product characteristics, November 2001 [2515]
Zomorodi K. Clin Pharmacol Drug Dev. Apr 2021; 10(4): 404-413
Pubmed , Volltext , DOI [10296]
Zor M. Int Urogynecol J. Jul 2015; 26(7): 959-66
Pubmed [8295]
Zoungas S. Diabetes Obes Metab. Apr 2020; 22 Suppl 2: 5-11
Pubmed [11786]
Zubieta, Demitrack. J Clin Pharmacol (1991) 11, 327-328 [1336]
Zubillaga I. Endocrinol Diabetes Nutr. Jan 2017; 64(6): 338-339
Pubmed [6373]
Zuchora B. Eur Neuropsychopharmacol. Jan 2005; 15(1): 85-93
Pubmed [9712]
Zullino DF. Br J Clin Pharmacol. Jan 2005; 59(1): 118-9; author reply 119
Pubmed [10815]
Zullino DF. Drugs Today (Barc). Jul 2004; 40(7): 603-19
Pubmed [4174]
Zullino DF. Int Clin Psychopharmacol. May 2002; 17(3): 141-3
Pubmed [1193]
Zumoff B. JAMA. May 1977; 237(18): 1960-1
Pubmed [792]
Zung S. Braz J Psychiatry. Mar 2006; 28(1): 84-5
Pubmed [8639]
Zuo XC. Drug Metab Pharmacokinet. Jan 2014; 29(4): 305-11
Pubmed [10194]
Zusammenfassung der zur Zulassung eingereichten Klinischen Studien: ZHANG, J: FDA Clinical Review of Olanzapine Pamoate Depot in the Treatment of Schizophrenie: http://www.fda.gov/ohrms/dockets/AC/08/slides/2008-4338s1-01-FDA-Zhang_files/frames.htm [3029]
Zwanzger P. J Clin Psychiatry. Mar 2001; 62(3): 208-9
Pubmed [1672]
Zwanzger P. Nervenarzt. May 2021; 92(5): 433-440
Pubmed [12421]
Zweers-Zeilmaker WM. Xenobiotica. Aug 1997; 27(8): 769-80
Pubmed [4510]
Zylber-Katz E. Ann Pharmacother. Feb 1995; 29(2): 127-31
Pubmed [6005]
Zylber-Katz E. Drug Intell Clin Pharm. Jun 1988; 22(6): 504-5
Pubmed [5573]
Bildrechte: © spinetta / Fotolia